聯環藥業(600513.SH)收到《藥品補充申請批件》
格隆匯8月21日丨聯環藥業(600513.SH)公佈,公司於近日收到江蘇省藥品監督管理局核准簽發的3個品種的《藥品補充申請批件》。藥品名稱分別為:“鹽酸屈他維林注射液”、“氨甲苯酸注射液”、“鹽酸託烷司瓊注射液”。
本次公司上述藥品的補充申請均由於公司吸收合併全資子公司揚州製藥有限公司,且公司實施退城進園整體搬遷至揚州生物健康產業園健康一路9號,上述藥品的生產企業名稱和生產場地發生變更,公司名稱及生產地址變更前後上述藥品的處方、工藝、原輔料、包材、生產設備的原理均未發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.